<DOC>
	<DOCNO>NCT00692445</DOCNO>
	<brief_summary>This multi-center , double blind , randomize , placebo-controlled , parallel group , flexible dose titration study conduct center USA India . Following washout period , subject treat citalopram 20 mg daily 4 week , 40 mg daily 4 week . Subjects tolerate 40 mg citalopram , whose MADRS score &lt; 50 % baseline , low 17 , consider partial non-responders randomize receive either placebo TC-5214 add-on therapy . TC-5214 placebo start 2 mg daily ( BID dose ) , titrate base tolerability therapeutic response 8 mg daily . Approximately 560 subject enter Open Label Phase approximately 220 enter double blind phase study .</brief_summary>
	<brief_title>TC-5214 add-on Treatment Major Depressive Disorder</brief_title>
	<detailed_description>This multi-center , double blind , randomize , placebo-controlled , parallel group , flexible dose titration study conduct center USA India . Following washout period , subject treat citalopram 20 mg daily 4 week , 40 mg daily 4 week . Subjects tolerate 40 mg citalopram , whose MADRS score reduce 50 % baseline , low 17 , consider partial non-responders randomize receive either placebo TC-5214 Add : -on therapy . TC-5214 placebo start 2 mg daily ( 1mg BID dose ) . After 2 week treatment , medication increase 4 mg ( 2mg BID ) continue unchanged . Dose escalation depend good tolerability inadequate therapeutic response . After 2 week , medication increase 8 mg ( 4mg BID ) felt appropriate investigator . Again , dose escalation depend good tolerability inadequate therapeutic response . At time double blind phase study , placebo TC-5214 reduce last previous dose level follow emergence unacceptable adverse event ( ) . If subject prematurely discontinue study Week 8 Week 16 reason , investigator make every effort perform evaluation per protocol , assume subject reach end double blind Add : -on treatment phase . These evaluation make soon possible within 2 week discontinuation . For subject complete double blind phase study , follow-up visit 2-3 week last dose trial medication . At follow-up , sign symptom relapse evaluate .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Diagnosis major depressive disorder ( MDD ) accord DSMIV confirm via MINI diagnostic scale 2 . No 1 prior antidepressant course treatment trial entry . 3 . Able give write informed consent . 4 . MADRS score great 27 . 5 . CGIS score great equal 4 . 6 . No clinically significant abnormality physical examination , vital sign , ECG laboratory test screen . 7 . Women child bear potential must : ) negative urine pregnancy test , b ) nursing , c ) willing use acceptable method contraception throughout study period . 1 . Any co morbid psychiatric illness confirm MINI diagnostic scale , especially bipolar disorder , schizophrenia , dementia , PTSD 2 . Subjects significant suicidal risk upon clinical assessment utilize M.I.N.I . 3 . History alcohol drug abuse last 6 month 4 . History seizures seizure disorder 5 . Any severe progressive uncontrolled medical condition 6 . For controlled medical condition , medication unchanged 2 month precede screening , else subject exclude 7 . Subjects Glaucoma , Kidney Disease Heart Disease 8 . Known hypersensitivity mecamylamine 9 . Other investigational drug previous 30 day 10 . Screening QTcB QTcF &gt; 450 msec 11 . Current prior citalopram treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>depression</keyword>
</DOC>